Exploring Treatment Strategies for Lymphoma: CAR T-Cell, Tafasitamab, and Clinical Trials

News
Video

An in-depth examination of relapsed/refractory DLBCL treatment options, including CAR T-cell therapy and tafasitamab, based on clinical trial data and patient eligibility.

Related Videos
Brooke Peters, PharmD, BCOP, a clinical pharmacist
Expert on DLBCL
Expert on DLBCL
Expert on DLBCL
Expert on DLBCL
Expert on DLBCL
Expert on DLBCL
Rafael Fonseca, MD, smiles at the camera on a white-and-yellow background.
Related Content